文献速递胸部技术与安全MR

COVID-19急性后综合征:129Xe MRI通气缺陷与1年后呼吸结局

Postacute COVID-19 Syndrome: 129Xe MRI Ventilation Defects and Respiratory Outcomes 1 Year Later.
PubMed 文献 · Radiology · 2023-02-07

前瞻性研究纳入53例COVID-19急性后综合征患者,在感染后3个月和15个月评估肺功能、运动能力、生活质量及129Xe MRI通气缺陷百分比(VDP)。结果显示VDP、FEV1%pred、DLCO%pred和SGRQ评分均显著改善,3个月VDP预测6分钟步行距离变化,3个月呼吸药物治疗与15个月生活质量改善相关。

要点

  • COVID-19急性后综合征患者15个月时129Xe MRI VDP较3个月显著降低(5.8% vs 4.2%)。
  • 3个月呼吸药物治疗与15个月生活质量改善相关(OR=4.0,95%CI 1.2–13.8)。

临床应用与阅片要点

  • 对COVID-19急性后综合征且肺功能正常者,129Xe MRI VDP可显示通气异常并随访变化。
  • 感染后3个月VDP较高可能提示后续运动能力改善空间,可结合呼吸药物治疗评估生活质量获益。

局限性

  • 样本量53例,来自两所四级医疗中心,可能存在选择偏倚。
  • 未设健康对照组,纵向观察不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background In individuals with postacute COVID-19 syndrome (PACS) and normal pulmonary function, xenon 129 (129Xe) MRI ventilation defects, abnormal quality-of-life scores, and exercise limitation were reported 3 months after infection; the longitudinal trajectory remains unclear. Purpose To measure and compare pulmonary function, exercise capacity, quality of life, and 129Xe MRI ventilation defect percent (VDP) in individuals with PACS evaluated 3 and 15 months after COVID-19 infection. Materials and Methods In this prospective study, participants with PACS aged 18-80 years were enrolled between July 2020 and August 2021 from two quaternary care centers. 129Xe MRI VDP, diffusing capacity of lung for carbon monoxide (Dlco), spirometry, oscillometry, 6-minute walk distance (6MWD), and St George Respiratory Questionnaire (SGRQ) scores were evaluated 3 months and 15 months after COVID-19 infection. Differences between time points were evaluated using the paired t test. Multivariable models were generated to explain exercise capacity and quality-of-life improvement. Odds ratios (ORs) were used to evaluate potential treatment influences. Results Overall, 53 participants (mean age, 55 years ± 18 [SD]; 27 women) attended both 3- and 15-month visits and were included in the analysis. The mean values for 129Xe MRI VDP (5.8% and 4.2%; P = .003), forced expiratory volume in the 1st second of expiration percent predicted (84% and 90%; P = .001), Dlco percent predicted (86% and 99%; P = .002), and SGRQ score (35 and 25; P < .001) improved between the 3- and 15-month visit. VDP measured 3 months after COVID-19 infection predicted the change in 6MWD (β = -0.643, P = .006), while treatment with respiratory medication at 3 months predicted an improved quality-of-life score at 15 months (OR, 4.0; 95% CI: 1.2, 13.8; P = .03). Conclusion Pulmonary function, gas exchange, exercise capacity, quality of life, and 129Xe MRI ventilation defect percent (VDP) improved in participants with postacute COVID-19 syndrome at 15 months compared with 3 months after infection. VDP measured at 3 months after infection correlated with improved exercise capacity, while treatment with respiratory medication was associated with an improved quality-of-life score 15 months after infection. ClinicalTrials.gov registration no. NCT05014516 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Vogel-Claussen in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kooner, McIntosh, Matheson, et al. Postacute COVID-19 Syndrome: 129Xe MRI Ventilation Defects and Respiratory Outcomes 1 Year Later. Radiology. 2023. PMID: 36749209. doi:10.1148/radiol.222557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。